Kisspeptin Dosage: What Human Studies Used (2026)

Not dosing advice. This page reports doses that studies and approved labels used, with their sources. It does not recommend a dose, and we do not give mixing, injection or unit-conversion instructions. Gray-market vials often do not contain what their label says. How we report doses.

Every dose studied in people

Study	Who	People	Dose and route	What happened
Kisspeptin-10: Yeung 2026, randomized single-blinded study	Healthy men	15	1.25 to 10.0 nmol/kg per hour; 180 nmol per hour nonstop; 150 nmol per hour for 8 hours a day Infusion under the skin · 8 hours, 5 days, or 12 days	The 8-hour infusions raised LH, FSH and testosterone against vehicle, more at higher rates (P < .0001)⁹. After 5 nonstop days, testosterone was still raised but LH and FSH were back at vehicle levels⁹. With 8 hours on and 16 hours off for 12 days, mean LH rose by 1.68 ± 0.25 IU/L on day 1 and 1.14 ± 0.33 IU/L on day 12, against −0.16 ± 0.19 on vehicle (P = .003), and a 1 nmol/kg bolus still raised gonadotropins at the end⁹. The paper reports 15 men recruited, with 7, 4 and 7 in the three parts and 12 more men as controls⁹.
Kisspeptin-10: NCT04648969, single-group phase 2 trial with posted results	Adults aged 18 and over with hypogonadotropic hypogonadism	18	20 IV doses over 40 hours, 4 dose levels in random order across 5 sets, then one GnRH dose; the record does not give the amounts IV boluses · 40 hours of dosing, measurements to 52 hours	Of the 18 people who started, 7 finished¹¹. In those 7, LH pulse amplitude rose by 0.35 ± 0.43 IU/L comparing before with during dosing, and by 0.19 ± 0.30 IU/L comparing before with after, while pulse frequency rose by 0.17 ± 0.27 pulses per hour¹¹. One serious adverse event was reported among the 18, rhabdomyolysis after the study visits were over, along with fatigue in 2 people¹¹. Results were first posted on 26 August 2026¹¹.
Kisspeptin-10: NCT05633966, phase 1 pump study, results not posted	Women aged 18 to 45 with hypothalamic amenorrhea or hypogonadotropic hypogonadism	13	Pulses about every 90 minutes; the record does not give the amount Pump under the skin · 2 weeks	The study finished on 31 August 2025, and no results had been posted as of 7 October 2026, so nothing is published about what this 2-week schedule did¹².
Kisspeptin-10: Ullah 2019, single-dose study across ages	Healthy men aged 25 to 27, 46 to 50 and 71 to 75	15	1 µg/kg, once IV bolus · Single dose, blood drawn for 120 minutes after it	LH rose in all three age groups, but testosterone rose only in the youngest group, which the authors read as the testes responding less with age¹³. FDA’s review lists the study as 5 men in each age band and gives its adverse events as not reported³.
Kisspeptin-10 and kisspeptin-54: Jayasena 2015, direct comparison with GnRH	Healthy men, 5 per dose group	–	0.1, 0.3 and 1.0 nmol/kg per hour of kisspeptin-10, of kisspeptin-54 and of GnRH, on separate days IV infusion · 3 hours per visit, visits at least a week apart	At 1.0 nmol/kg per hour, the area under the LH curve was 10.81 ± 1.73 h.IU/L on kisspeptin-10, 14.43 ± 1.27 on kisspeptin-54 and 34.06 ± 5.18 on GnRH¹⁴. LH and FSH ran about 3 times higher on GnRH than on kisspeptin-10 and about 2 times higher than on kisspeptin-54, and the two kisspeptin forms were similar to each other¹⁴. Peak LH came at the middle rate, 0.3 nmol/kg per hour, in every group, and testosterone was not measured³.
Kisspeptin-10: George 2013, proof-of-concept study in type 2 diabetes	Men with type 2 diabetes and low testosterone, plus age-matched healthy men	12	0.3 µg/kg once; then 4 µg/kg per hour in 4 of the men with diabetes IV bolus, then IV infusion · Single dose; the infusion ran 11 hours on one day	The single dose raised mean LH from 5.5 ± 0.8 to 13.9 ± 1.7 IU/L in the healthy men and from 4.7 ± 0.7 to 10.7 ± 1.2 IU/L in the men with diabetes, a similar change in both¹⁵. During the 11-hour infusion in 4 men with diabetes, LH rose from 3.9 ± 0.1 to 20.7 ± 1.1 IU/L, testosterone from 8.5 ± 1.0 to 11.4 ± 0.9 nmol/L, and LH pulse frequency from 0.6 ± 0.1 to 0.9 pulses per hour¹⁵.
Kisspeptin-10: Jayasena 2011, dose-finding study in men and women	Healthy men, and healthy women in the first half of the cycle or just before ovulation	46	0.3 to 10 nmol/kg by IV; 2 to 32 nmol/kg under the skin; 20 to 720 pmol/kg per minute by IV IV bolus, injection under the skin, IV infusion · Single doses; the infusions ran 90 minutes	In men, LH rose at every IV dose from 0.3 nmol/kg up and FSH at 1.0 and 3.0 nmol/kg, with the largest LH rise at 10 nmol/kg¹⁶. In women in the first half of the cycle, no reproductive hormone changed at any dose by any of the three routes¹⁶. In 5 women dosed just before ovulation, 10 nmol/kg by IV raised both LH and FSH¹⁶. Each dose group held 4 to 5 people¹⁶.
Kisspeptin-10: George 2011, dose-response and infusion study	Healthy men	–	0.01 to 3.0 µg/kg as single doses; then a 3 µg/kg dose followed by 4 µg/kg per hour, or 1.5 µg/kg per hour IV bolus, then IV infusion · Single doses a week or more apart; infusions of 22.5 hours and 9 hours	LH peaked at 1 µg/kg, rising from 4.1 ± 0.4 to 12.4 ± 1.7 IU/L at 30 minutes in 6 men, and the larger 3 µg/kg dose gave a smaller rise⁴. The 22.5-hour infusion in 4 men raised mean LH from 5.4 ± 0.7 to 20.8 ± 4.9 IU/L and testosterone from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/L⁴. The 9-hour infusion at the lower rate raised mean LH from 5.2 ± 0.8 to 14.1 ± 1.7 IU/L and LH pulse frequency from 0.7 ± 0.1 to 1.0 ± 0.2 pulses per hour in 4 men⁴. The 4 µg/kg per hour rate was picked to deliver an hourly amount close to the most effective single doses, given how fast kisspeptin-10 clears⁴. The paper reports no adverse events⁴.
Kisspeptin-54: Mills 2025, randomized crossover nasal spray study	Healthy men, healthy women, and women with hypothalamic amenorrhea	34	3.2, 6.4, 12.8 and 25.6 nmol/kg in the men; 12.8 nmol/kg in both groups of women Nasal spray, four sprays per visit · One dose per visit, visits a week apart	LH peaked 30 to 45 minutes after dosing¹⁷. In the men the largest mean rise above baseline came at 12.8 nmol/kg, 4.4 ± 0.6 IU/L, and the rise at 25.6 nmol/kg was smaller than that¹⁷. At 12.8 nmol/kg the mean rise was 1.4 ± 0.3 IU/L in healthy women and 4.4 ± 0.2 IU/L in women with hypothalamic amenorrhea¹⁷. The groups were 12 men, 12 healthy women and 10 women with amenorrhea, and the paper reports no side effects or adverse events¹⁷.
Kisspeptin-54: Jayasena 2014, dose-window infusion study	Women with hypothalamic amenorrhea	5	0.01, 0.03, 0.10, 0.30 and 1.00 nmol/kg per hour, one rate per visit, against vehicle IV infusion · 8 hours per visit, 10 hours at the top rate	LH pulses rose from 1.6 ± 0.4 per 8 hours on vehicle to 5.0 ± 0.5 at each woman’s best rate, and that rate was different for each woman¹. Pulse secretory mass rose from 3.92 ± 2.31 to 23.44 ± 12.59 IU/L¹. Rates of 0.01 to 0.30 nmol/kg per hour showed no fading, but at 1.00 nmol/kg per hour mean LH was 22.03 ± 5.42 IU/L between 241 and 360 minutes and 12.57 ± 3.05 IU/L between 481 and 600 minutes (P < .01)¹.
Kisspeptin-54: Jayasena 2010, twice-weekly dosing study	Women with hypothalamic amenorrhea	–	Twice a week; the abstract does not give the amount Injection · 8 weeks	Twice-weekly injections caused only partial loss of response, against the complete tolerance that twice-daily injections produced, and reproductive hormones were still higher than on saline after 8 weeks¹⁰. In the twice-daily comparison the LH response faded gradually while the FSH response was nearly gone by day 2¹⁰. No adverse effects were observed, and the abstract gives neither the dose nor the number of women¹⁰.
Kisspeptin-54: Jayasena 2009, randomized twice-daily trial	Women with hypothalamic amenorrhea, 5 per group	10	6.4 nmol/kg twice a day, against saline Injection under the skin · 2 weeks	On the first injection day, LH rose by 24.0 ± 3.5 IU/L and FSH by 9.1 ± 2.5 IU/L within 4 hours⁸. On the 14th injection day the same dose raised LH by 2.5 ± 2.2 IU/L and FSH by 0.5 ± 0.5 IU/L (P < 0.05 against day 1)⁸. The women still responded to GnRH, and neither LH pulses nor ovarian ultrasound measurements changed over the 2 weeks⁸.
Kisspeptin-54: Dhillo 2005, placebo-controlled crossover study	Healthy men	6	4 pmol/kg per minute, against saline IV infusion · 90 minutes per visit	Mean LH over the 90 minutes was 10.8 ± 1.5 U/L on kisspeptin against 4.2 ± 0.5 on saline, FSH 3.9 ± 0.7 against 3.2 ± 0.6, and testosterone at 180 minutes 24.9 ± 1.7 nmol/L against 21.7 ± 2.2, all with P < 0.001⁶.
Kisspeptin-54: Mills 2025, randomized crossover anxiety study	Healthy adults, 63 male and 32 female	95	1 nmol/kg per hour, once, against a rate-matched placebo IV infusion · 75 minutes per visit	LH rose to the levels earlier studies reported at this rate, which the authors took as proof the dose was active (P < .001)¹⁸. Anxiety scores did not change against placebo (P = .13), nor did cortisol (P = .73), systolic (P = .74) or diastolic blood pressure (P = .90), or heart rate (P = .52)¹⁸.
Kisspeptin-54: Mills 2023, randomized crossover trial	Men with hypoactive sexual desire disorder, a persistent low sex drive that causes distress	32	1 nmol/kg per hour, once, against a rate-matched placebo IV infusion · 75 minutes per visit, visits at least 7 days apart	Penile swelling during an 8-minute sexual video ran up to 56% higher than on placebo, a mean difference of 0.28 on the study’s swelling scale (95% CI 0.04 to 0.52, P = .02)¹⁹. Self-reported happiness about sex rose by 0.63 points (95% CI 0.10 to 1.15, P = .02)¹⁹. Of 37 men randomized, 32 finished, and the paper reports no side effects or adverse events¹⁹.
Kisspeptin-54: Thurston 2022, randomized crossover trial	Premenopausal women with hypoactive sexual desire disorder	32	1 nmol/kg per hour, once, against an equal volume of placebo IV infusion · 75 minutes per visit, visits at least a month apart	Brain responses to erotic videos and to attractive faces changed against placebo, and the more one brain area (the posterior cingulate cortex) responded to attractive male faces, the less sexual aversion the women reported (r = −0.476, P = .005)²⁰. Estradiol, progesterone and testosterone did not change, and no adverse effects were reported²⁰. Of 40 women randomized, 32 completed both visits²⁰.
Kisspeptin-54: Yang 2020, randomized crossover study	Healthy heterosexual men, mean age 24.5 years	33	1 nmol/kg per hour, once, against placebo IV infusion · 75 minutes per visit	The infusion raised LH, which the authors took as proof that the dose was biologically active, while testosterone did not change over the 75 minutes²¹. Brain responses to scents and faces linked to attraction increased, and the effects were larger in men with lower baseline reward drive and sexual quality-of-life scores²¹. Of 36 men recruited, 33 made up the final group²¹.
Kisspeptin-54: Comninos 2017, randomized crossover study	Healthy young men	29	1 nmol/kg per hour, once, against vehicle IV infusion · 75 minutes per visit	The authors chose this rate to hold kisspeptin steady from 30 to 75 minutes while avoiding any rise in testosterone during the scan²². Activity rose in brain areas tied to sexual and couple-bonding images but not for neutral, happy or fearful ones, and negative mood fell (P = 0.031)²². Of 31 men studied, 2 were dropped for excessive head motion, leaving 29²².
Kisspeptin-54: Abbara 2017, randomized placebo-controlled trial	Women aged 18 to 34 at high risk of ovarian hyperstimulation syndrome during IVF	62	9.6 nmol/kg once, then either a second 9.6 nmol/kg dose or saline 10 hours later Injection under the skin · One IVF cycle; the first dose came 36 hours before egg retrieval	An egg yield of at least 60% was reached by 22 of 31 women on two doses (71.0%) against 14 of 31 on one (45.2%), a difference of 25.8% (95% CI 2.1 to 49.5, P = 0.042)²³. One woman in the single-dose group had moderate early ovarian hyperstimulation syndrome and one in the two-dose group had a mild late case²³.
Kisspeptin-54: Abbara 2015, adaptive dose-finding trial	Women at high risk of ovarian hyperstimulation syndrome during IVF	60	3.2, 6.4, 9.6 or 12.8 nmol/kg, once Injection under the skin · One IVF cycle, 36 hours before egg retrieval	At least one mature egg came from 57 of the 60 women (95%)⁵. The highest egg yield, 121% of the follicles measured before the trigger, followed 12.8 nmol/kg, but the highest pregnancy rates followed 9.6 nmol/kg: 85% biochemical, 77% clinical and 62% live births per transfer, against 63%, 53% and 45% across all doses⁵. Three women had mild early ovarian hyperstimulation syndrome and one a mild late case, with no moderate, severe or critical cases and no one needing treatment for it⁵. The adaptive design left 5 women at 3.2 nmol/kg, 20 at 6.4, 15 at 9.6 and 20 at 12.8⁵.
Kisspeptin-54: Jayasena 2014, IVF trigger dose study	Women having IVF with at least three follicles of 18 mm or more	53	1.6 nmol/kg in 2 women, 3.2 in 3, 6.4 in 24 and 12.8 in 24 Injection under the skin · Single dose, 36 hours before egg retrieval	Eggs matured at every dose, and the mean number of mature eggs per woman generally rose with the dose²⁴. Fertilization and embryo transfer followed in 49 of 53 women (92%), the biochemical pregnancy rate was 40% (21 of 53) and the clinical pregnancy rate 23% (12 of 53)²⁴. Ten of those 12 women gave birth to healthy babies and two miscarried²⁴.

Studies, animals and users: kept apart

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

Kisspeptin-10: single IV boluses of 0.01 to 3 µg/kg in healthy men, with the largest LH rise at 1 µg/kg, and IV infusions of 1.5 or 4 µg/kg per hour for up to 22.5 hours⁴; 4 µg/kg per hour by IV for 11 hours in men with type 2 diabetes¹⁵; one 1 µg/kg IV dose in men of different ages¹³. FDA’s review lists the highest human exposures as 13 µg/kg by IV bolus, a single 42 µg/kg injection under the skin in women, and 12.5 µg/kg per hour by IV for 24 hours. It found no published trial that gave kisspeptin-10 on a fixed schedule for more than one day³. Infusions under the skin in healthy men: 1.25 to 10 nmol/kg per hour for 8 hours, 180 nmol per hour nonstop for 5 days, and 150 nmol per hour for 8 hours a day for 12 days⁹. A Boston study gave 20 IV doses over 40 hours to people with hypogonadotropic hypogonadism, and a later one used a pump that gave a pulse under the skin about every 90 minutes for 2 weeks¹¹¹². Kisspeptin-54: 1 nmol/kg per hour by IV for 75 minutes in the libido, attraction and anxiety studies¹⁸¹⁹²⁰; single injections of 1.6 to 12.8 nmol/kg under the skin as an IVF trigger, with the highest pregnancy rates at 9.6 nmol/kg⁵²⁴; 6.4 nmol/kg under the skin twice daily for 2 weeks in hypothalamic amenorrhea, which lost most of its effect⁸, and twice-weekly injections for 8 weeks¹⁰; 12.8 nmol/kg as a nasal spray¹⁷. We found no published trial of once-daily kisspeptin-10 shots, the regimen sold online.

In animal studies

Monkeys: nonstop IV kisspeptin-10 at 1,200 or 4,800 µg/kg per day raised LH for only about 3 hours, while 2 µg one-minute IV pulses every hour for 48 hours triggered repeated LH and FSH pulses³. Mice prone to atherosclerosis: 5 or 12.5 µg/kg per hour by pump under the skin for 4 weeks sped plaque growth, so no dose was free of adverse effects³²⁶. Dogs: 30, 100 or 1,000 µg/kg IV once daily for 14 days, with no drug-related toxicity even at the top dose²⁷. Rats: half-life under 1 minute after 1 mg/kg IV³.

What users report Anecdotal · not validated · not a recommendation

A 2026 dosing-guide website lists 100 to 200 µg of kisspeptin-10 under the skin once a day²⁵.

Half-life and how it is taken

Half-life: About 4 minutes for kisspeptin-10 and about 28 minutes for kisspeptin-54, both measured by IV³Kisspeptin-10: 3.8 minutes in men and 4.1 minutes in women, measured during and after an IV infusion (Jayasena 2011, as summarized by FDA); under 1 minute in rats after an IV injection³. Kisspeptin-54: 27.6 minutes in 6 men during a 90-minute IV infusion⁶. No half-life has been published for kisspeptin-10 injected under the skin, the way it is sold.
Routes: Intravenous bolus or infusion (most human studies of both forms, including the libido brain-scan trials)
Subcutaneous injection or pump (kisspeptin-54 in IVF and amenorrhea trials; kisspeptin-10 as single shots in women and by infusion for up to 12 days in men; the usual clinic and gray-market route)
Intranasal spray (kisspeptin-54 in one 2025 crossover study)
Intramuscular injection (proposed in the 2024 compounding nomination; no human data found)
Troches dissolved in the mouth (offered by some compounders per FDA; no human data found)

Two molecules, two sets of units

Kisspeptin-10 is the tail of kisspeptin-54. In the human precursor protein, kisspeptin-54 runs from residue 68 to 121 and kisspeptin-10 from 112 to 121²⁸. They are different molecules of different weight, and the studies dose them in different units, so this page reports each dose in the units its own paper used and does not convert between them. The table lists the kisspeptin-10 studies first, then the kisspeptin-54 studies in three groups: hormone studies, libido, mood and brain-scan studies, and IVF trigger studies, most recent first within each group.

Some kisspeptin-10 studies set the dose by weight: µg per kilogram for single doses and µg per kilogram per hour for drips⁴¹⁵. Others, and all the kisspeptin-54 studies, set it by amount of substance: nmol per kilogram, nmol per kilogram per hour, nmol per hour, or pmol per kilogram per minute⁶⁹¹⁶. A per-kilogram dose is not a fixed amount, and an amount of substance is not a weight, so two numbers from two papers cannot be lined up by eye.

Only one study gave both forms to the same people at the same rates. At 0.1, 0.3 and 1.0 nmol/kg per hour by IV for 3 hours, kisspeptin-10 and kisspeptin-54 raised LH to a similar degree, and both less than GnRH¹⁴. It matched the rates, not the effects, so it does not turn a kisspeptin-54 dose into a kisspeptin-10 dose¹⁴.

More was not better

The biggest dose tested was not the strongest. In the first kisspeptin-10 dose-response study in men, 3 µg/kg produced a smaller LH rise than 1 µg/kg, and the mean LH it reached was significantly lower than after 0.3 and 1 µg/kg⁴. The authors wrote that ‘the reduced stimulatory efficacy of kisspeptin-10 at high concentrations demands careful dosing’⁴.

Other routes show the same ceiling. In the 3-hour comparison study, peak LH came at the middle rate, 0.3 nmol/kg per hour, in every group, kisspeptin and GnRH alike³. With the nasal spray, the largest mean LH rise in men came at 12.8 nmol/kg, and 25.6 nmol/kg gave a smaller rise than that¹⁷.

Who is dosed matters as much as how much. In women in the first half of the menstrual cycle, no reproductive hormone moved after kisspeptin-10 at up to 10 nmol/kg by IV, 32 nmol/kg under the skin or 720 pmol/kg per minute by drip, while the same molecule worked in men and in women dosed just before ovulation¹⁶.

Why the same dose stops working

Kisspeptin-54 twice a day wore its own response out. On the first day, 6.4 nmol/kg under the skin raised LH by 24.0 ± 3.5 IU/L within 4 hours; on the 14th injection day the same dose raised it by 2.5 ± 2.2 IU/L⁸. Those women still responded to GnRH, so the pituitary had not run dry⁸.

Spacing the injections out changed that. With twice-daily dosing the FSH response was nearly gone by day 2, while twice-weekly dosing caused only partial loss of response and left reproductive hormones higher than saline after 8 weeks¹⁰.

The fade can set in inside a single long drip. In 5 women with hypothalamic amenorrhea, rates of 0.01 to 0.30 nmol/kg per hour showed none, but at 1.00 nmol/kg per hour mean LH fell from 22.03 ± 5.42 IU/L between 241 and 360 minutes to 12.57 ± 3.05 IU/L between 481 and 600 minutes (P < .01)¹. A GnRH test straight after that drip matched one a week later, which points at the kisspeptin receptor rather than the pituitary¹.

Kisspeptin-10 behaves the same way when it never stops. Five days of nonstop infusion under the skin left testosterone raised but LH and FSH back at vehicle levels, while 8 hours on and 16 hours off for 12 days kept LH raised, and a bolus still worked at the end⁹. The nasal-spray authors describe this as desensitization of the kisspeptin receptor, met mostly with frequent high doses¹⁷.

Longer-lasting relatives are different molecules

Two lab-made molecules that act on the same receptor have human doses of their own, and those doses say nothing about kisspeptin. In healthy men given TAK-448 under the skin for 14 days, doses above 0.1 mg a day dropped testosterone below the castration range by day 8, the opposite of what short kisspeptin exposure does²⁹. In healthy women, MVT-602 at 0.01 and 0.03 nmol/kg produced an LH rise of similar size to 9.6 nmol/kg of kisspeptin-54, but it peaked at 21.4 hours instead of 4.7 hours². Different molecule, different dose, different time course².

What is sold, and what was tested

The 2024 compounding nomination asked for kisspeptin-10 as 1 mg/mL solutions for injection under the skin or into muscle³. FDA found it compounded as a 100 µg/mL injection and a 200 µg troche at one site and as 100 µg/mL and 200 µg/mL injections at another, while other sites sold kisspeptin-10 as a 10 mg product for research use³. Those are fixed strengths, while the studies above set the amount by body weight³⁴.

FDA’s review also set out how long kisspeptin-10 had been given at a stretch. In the IV bolus studies the longest run was one dose an hour for 11 hours on a single day, the longest drip ran 24 hours, and many studies gave only one or two doses³. It found no study of injection into muscle at all³.

There is also no official standard for what a vial should hold. FDA found no kisspeptin-10 monograph in the United States Pharmacopeia or the National Formulary, and none in the European or Japanese pharmacopeia³.

Longer schedules are being tested. Two pump studies, one giving pulses every 60 to 240 minutes and one about every 90 minutes for 2 weeks, were listed as recruiting when their records were updated on 13 July 2026³⁰³¹. With the finished pump study’s results still unposted, the only published kisspeptin-10 schedule longer than a day is the 12-day infusion study in healthy men⁹¹².

Questions people ask

How much kisspeptin should I take?

No dose is established for any use, and no medicine containing either form is approved³. Human studies gave it in a research unit, nearly always as one dose or a drip of a few hours, by IV, by infusion under the skin or as a nasal spray, with the amount set by body weight⁴⁹¹⁷. US pharmacies may not compound kisspeptin³²³³³⁴.

What dose of kisspeptin is used in IVF?

The IVF trials used a single kisspeptin-54 injection under the skin 36 hours before egg retrieval, at 1.6 to 12.8 nmol/kg, with the highest pregnancy rates at 9.6 nmol/kg⁵²⁴. A later trial gave a second 9.6 nmol/kg dose 10 hours after the first, which raised the share of women reaching a good egg yield from 45.2% to 71.0%²³. Those doses were given inside hospital IVF programs⁵²³.

What kisspeptin dose did the libido studies use?

All four brain-scan studies used the same thing: kisspeptin-54 at 1 nmol/kg per hour by IV drip for 75 minutes, once, against placebo^19202122. The rate was picked to hold steady levels during the scan while avoiding a rise in testosterone²². Each of those doses was given by drip in a hospital research unit¹⁹²⁰.

Does kisspeptin stop working if you use it every day?

In the repeat-dosing studies, the response faded when doses came often or never stopped: twice-daily kisspeptin-54 lost most of its effect within 2 weeks, and 5 days of nonstop kisspeptin-10 infusion left LH and FSH back at vehicle levels⁸⁹. Spaced-out schedules held up better, with 8-hour daily infusions keeping LH raised for 12 days and twice-weekly injections still working at 8 weeks⁹¹⁰.

Are kisspeptin-10 and kisspeptin-54 dosed the same way?

No. The papers dose them in different units, and this page does not convert between them⁴⁵. In the one study that gave both to healthy men at matched rates of 0.1, 0.3 and 1.0 nmol/kg per hour by IV, the two forms raised LH to a similar degree, and both less than GnRH¹⁴.

Go deeper

Sources

1Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54 The Journal of Clinical Endocrinology & Metabolism, Jun 2014. pubmed.ncbi.nlm.nih.gov
2Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders The Journal of Clinical Investigation, 1 Dec 2020. pubmed.ncbi.nlm.nih.gov
3FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: kisspeptin-10 (FDA evaluation dated 5 July 2024) U.S. Food and Drug Administration, 5 Jul 2024. fda.gov
4Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men The Journal of Clinical Endocrinology & Metabolism, Aug 2011. pubmed.ncbi.nlm.nih.gov
5Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy The Journal of Clinical Endocrinology & Metabolism, Sep 2015. pubmed.ncbi.nlm.nih.gov
6Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males The Journal of Clinical Endocrinology & Metabolism, Dec 2005. pubmed.ncbi.nlm.nih.gov
7Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
8Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis The Journal of Clinical Endocrinology & Metabolism, Nov 2009. pubmed.ncbi.nlm.nih.gov
9Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men European Journal of Endocrinology, 3 Aug 2026. pubmed.ncbi.nlm.nih.gov
10Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea Clinical Pharmacology & Therapeutics, Dec 2010. pubmed.ncbi.nlm.nih.gov
11Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism (NCT04648969) ClinicalTrials.gov, 26 Aug 2026. clinicaltrials.gov
12Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders (NCT05633966) ClinicalTrials.gov, 3 Oct 2025. clinicaltrials.gov
13Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men Andrologia, May 2019. pubmed.ncbi.nlm.nih.gov
14Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men Human Reproduction, Aug 2015. pubmed.ncbi.nlm.nih.gov
15Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism Clinical Endocrinology, Jul 2013. pubmed.ncbi.nlm.nih.gov
16The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans The Journal of Clinical Endocrinology & Metabolism, Dec 2011. pubmed.ncbi.nlm.nih.gov
17Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans eBioMedicine, May 2025. pubmed.ncbi.nlm.nih.gov
18Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans The Journal of Clinical Endocrinology & Metabolism, 16 Oct 2025. pubmed.ncbi.nlm.nih.gov
19Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial JAMA Network Open, 1 Feb 2023. pubmed.ncbi.nlm.nih.gov
20Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial JAMA Network Open, 3 Oct 2022. pubmed.ncbi.nlm.nih.gov
21Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men JCI Insight, 13 Feb 2020. pubmed.ncbi.nlm.nih.gov
22Kisspeptin modulates sexual and emotional brain processing in humans The Journal of Clinical Investigation, 1 Feb 2017. pubmed.ncbi.nlm.nih.gov
23A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial Human Reproduction, 1 Sep 2017. pubmed.ncbi.nlm.nih.gov
24Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization The Journal of Clinical Investigation, Aug 2014. pubmed.ncbi.nlm.nih.gov
25Kisspeptin Dosage: 10 mg Vial PeptideDosages, 20 Sep 2026. peptidedosages.com
26Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist Journal of the American Heart Association, 14 Apr 2017. pubmed.ncbi.nlm.nih.gov
27Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog International Journal of Toxicology, Jul 2021. pubmed.ncbi.nlm.nih.gov
28KISS1_HUMAN (Q15726): Metastasis-suppressor KiSS-1 UniProt, 2 Sep 2026. uniprot.org
29Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies The Journal of Clinical Endocrinology & Metabolism, Aug 2014. pubmed.ncbi.nlm.nih.gov
30Kisspeptin Administration Subcutaneously to Patients With IHH (NCT05896293) ClinicalTrials.gov, 13 Jul 2026. clinicaltrials.gov
31Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea (NCT07224438) ClinicalTrials.gov, 13 Jul 2026. clinicaltrials.gov
32Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
33Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
34Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov

Not medical advice. Talk to a licensed clinician before using any drug. Report an error.